SCHEMBL3663393

SCHEMBL3663393

CCCC1(c2ccccc2)NC(=O)N(CC(=O)c2ccc(NC(=O)CC(C)C)cc2F)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
LMNA P02545 2/20 0.51
MAPT P10636 2/20 0.48
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
KDM4A O75164 1/20 0.46
USP2 O75604 1/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716864 0.93 MAPT (0.56) KMT2AMAPTPOLBPKMUSP2
SCHEMBL4122445 0.89 KMT2A (0.55) KMT2ALMNAMAPTALDH1A1HTT
SCHEMBL3660062 0.87 KMT2A (0.55) KMT2ALMNAPOLBMEN1
SCHEMBL3662112 0.86 KCNH2 (0.57) KMT2AMAPTALDH1A1MEN1
SCHEMBL4113485 0.81 KDM4A (0.52) KMT2ALMNAMAPTALDH1A1HTT
SCHEMBL3661725 0.80 LMNA (0.55) KMT2ALMNAMAPTALDH1A1HTT
SCHEMBL3664010 0.80 LMNA (0.55) KMT2ALMNAMAPTALDH1A1HTT
SCHEMBL3660498 0.78 KMT2A (0.61) KMT2AMAPTPOLBPKMUSP2
SCHEMBL3796712 0.78 HDAC6 (0.46) KMT2AMAPTPOLBPKMMEN1
SCHEMBL3656018 0.74 KMT2A (0.51) KMT2ALMNAPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2212314-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS Novartis AG (CH) 2010-08-04 EP disclosed
WO-2009050200-A1 IMIDAZOLIDINE-2,4-DIONE (HYDANTOIN) DERIVATIVES USEFUL AS NPY Y2 RECEPTOR MODULATORS NOVARTIS AG (CH) 2009-04-23 WO disclosed
US-20090099243-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099243-A1 ORGANIC COMPOUNDS SLCO4C1, SLCO1B1, SLCO1B3 KMT2A 2020/4885LMNA 2430/4885MAPT 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.